Pembrolizumab Not Active Against Cisplatin-Refractory Testicular Cancer

In a small phase II study of 12 men with nonseminoma germ cell tumors refractory to cisplatin, pembrolizumab did not demonstrate clinical activity.

Source: CancerNetwork - November 27, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Genitourinary Cancers News Testicular Cancer Source Type: news